百龙创园: 股东减持股份结果公告

Core Viewpoint - The announcement details the shareholding structure and the results of a share reduction plan by major shareholders of Shandong Bailong Chuangyuan Biotechnology Co., Ltd, indicating significant changes in ownership percentages and the completion of the planned share reduction [1][2][3]. Shareholding Structure - Major shareholders include Qingdao Enfu Kaijin Venture Capital Fund Partnership (Limited Partnership) holding 1.47% and Guo Enyuan holding 2.16%, collectively owning 12.49% of the company with a total of 40,343,524 shares [1][2]. - The total share capital of the company is now 420,012,320 shares after a capital increase [2]. Share Reduction Plan Results - The share reduction plan was completed by June 25, 2025, with Qingdao Kaijin and its action group reducing their holdings by a total of 16,928,000 shares, representing 4.95% of the total share capital [1][3]. - Qingdao Kaijin reduced its shares by 14,354,000, while Jiaxing Enfu reduced by 2,574,000 shares, with respective ownership percentages post-reduction being 4.20% and 0.75% [1][3]. - The reduction was executed through block trading, with share prices ranging from 15.93 to 28.06 yuan per share, resulting in total proceeds of approximately 308 million yuan for Qingdao Kaijin and about 55 million yuan for Jiaxing Enfu [3].